Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial

What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis

“…Four studies [18,19,21,24] were specifically devoted to PS2 patients, while two trials [22,25] reported subgroup analysis for PS2 patients (18 and 20%, respectively) within larger randomized phase III trials. All trials compared a platinumbased doublet with single-agent chemotherapy; four of these [18,21,22,24] compared carboplatin-based doublet with single agent chemotherapy: carboplatin plus pemetrexed vs pemetrexed alone [18], carboplatin plus gemcitabine vs gemcitabine alone [21,24], carboplatin plus paclitaxel vs paclitaxel alone [22,25]; the other two trials compared cisplatin plus gemcitabine with gemcitabine alone [19] and cisplatin plus vinorelbine or vindesine with vinorelbine alone [23]. In nearly every trial characteristics were well balanced between two arms.…”

“…So this is the only study included in our meta-analysis with missing haematological toxicity data. A French study [25] of carboplatin-paclitaxel compared with weekly paclitaxel alone was devoted to elderly patients with advanced NSCLC, but included 123 patients (27.3% of study population) with PS 2. Anyway the extraction of specific outcome measurements and toxicity for PS2 patients is not possible and therefore we had to exclude this study.…”

Fall-related injuries in elderly cancer patients treated with neurotoxic chemotherapy: A retrospective cohort study

“…1 Studies have shown that fit older patients with cancer may benefit from chemotherapy as much as younger patients. [2][3][4] As the age of patients with cancer treated with chemotherapy continues to rise, there is a growing need to recognize and try to prevent complications of treatment that are common in this population. Fall-related injuries (FRIs) are a frequent cause of morbidity and mortality in the elderly.…”

Reasonable Choices for Cytotoxic or Cytostatic Treatment in Elderly Advanced Non-Small Cell Lung Cancer Patients

“…The combination produced better OS compared with single -agent with the cost of increased toxicity (especially neutropenia). Patients in both arms received erlotinib at the Time of Progression [10]. Nab-paclitaxel alone chemotherapy showed beneficial results as far as median OS is concerned with manageable toxicities [11].…”